gemtuzumab ozogamicin
Term · Oncology and biomedicine · MLC-T-ONC-003465
A drug used alone or with other drugs to treat acute myeloid leukemia that is CD33 positive (expresses the protein CD33). It is used in adults and in children aged 1 month and older whose disease is newly diagnosed. It is also used in adults and in children aged 2 years and older whose disease has come back or has not gotten better with other treatment. It is also being studied in the treatment of other types of cancer. Gemtuzumab ozogamicin contains a monoclonal antibody that binds to CD33, which is found on some leukemia cells. It also contains an anticancer drug, which may help kill cancer cells. Gemtuzumab ozogamicin is a type of antibody-drug conjugate. Also called Mylotarg.
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis.
| Identifier | MLC-T-ONC-003465 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Mylotarg; Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody; hP67.6-Calicheamicin |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-003465",
"term": "gemtuzumab ozogamicin",
"field": "Oncology and biomedicine",
"definitions": [
"A drug used alone or with other drugs to treat acute myeloid leukemia that is CD33 positive (expresses the protein CD33). It is used in adults and in children aged 1 month and older whose disease is newly diagnosed. It is also used in adults and in children aged 2 years and older whose disease has come back or has not gotten better with other treatment. It is also being studied in the treatment of other types of cancer. Gemtuzumab ozogamicin contains a monoclonal antibody that binds to CD33, which is found on some leukemia cells. It also contains an anticancer drug, which may help kill cancer cells. Gemtuzumab ozogamicin is a type of antibody-drug conjugate. Also called Mylotarg.",
"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis."
],
"synonyms": [
"Mylotarg",
"Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody",
"hP67.6-Calicheamicin"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/gemtuzumab-ozogamicin/"
}
Record 7,883 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.